Sertoli cells (SCs) function as ''nurse cells,'' which play crucial roles in supporting spermatogenesis through establishing a unique and essential environment in the male reproductive tract. Given the important roles of SCs in male fertility, this study was designed to evaluate the effect of diosgenin, an aglycone of the steroidal saponin, on TM4 cell proliferation and to elucidate the possible mechanisms. We showed that diosgenin increased the proliferation of TM4 cell and primary SCs in a time-and concentration-dependent manner. Diosgenin increased cyclins D1 and E as well as CDK4/6 and CDK2 expression but inhibited P27 expression, with no significant alterations of cyclin B and cdc2 (cell division cycle 2), resulting in cell-cycle G 1 /S transition. Diosgenin significantly inhibited apoptosis, as reflected by decreased percentage of TUNELpositive cells; decreased expression of Bax (Bcl-2-associated X protein), AIF (apoptosis-inducing factor), and cleaved caspases 3 and 9; and increased expression of Bcl-2 (B-cell lymphoma 2). Diosgenin induced an immediate and transient plasma membrane translocation of ESR1 and ESR2 from the nucleus, which was inhibited by the antiestrogen ICI 182 780 and PP2, an inhibitor of SRC. Moreover, ICI 182 780 and PP2 significantly inhibited diosgenin-induced cell-cycle transition and inhibition of apoptosis. Activation of extracellular regulated protein kinase (ERK)/Akt signaling was also involved in diosgenin-induced TM4 cell proliferation, which was SRC-and ESR-dependent. Furthermore, diosgenin induced late activation of nuclear ESR transcriptional activity, which in turn directly regulated cell cycle and apoptosis-related factors, such as cyclin D and Bcl-2. Taken together, the results show that diosgenin activated SRC-ESR translocation-ERK/Akt-ESR transcriptional activity, leading to cell-cycle transition and inhibition of apoptosis and thus final cell proliferation. These findings may better our understanding of the pharmacological actions of diosgenin and advance therapeutic approaches to male infertility.
INTRODUCTION
Over the last 50 yr, numerous studies have suggested deterioration in the quality of male human reproductive function [1, 2] . Sertoli cells (SCs) function to create a unique and essential environment in the adluminal compartment, providing structural support, nutrition, and immunological protection to the progression of spermatogenesis [3] [4] [5] . Thus, SCs have been defined as ''nurse cells'' within the seminiferous epithelium [6] , playing a crucial role in establishing an adequate luminal environment in the male reproductive tract [5] . A single SC can only support 30-50 germ cells [7] , indicating that the final number of SCs sets the upper limit for testicular sperm production and, to a degree, determines the level of male fertility [8, 9] . In adult rodents, the number of SCs is established before weaning [10, 11] . Therefore, regulation of SC proliferation is of great importance for male fertility.
Estrogens are believed to play important roles in the development and maintenance of reproductive function and fertility [12] . Biological effect of estrogens is mainly mediated through two estrogen receptors, ESR1 and ESR2 (also known as ERa and ERb, respectively), both belonging to the nuclear receptor family of transcription factors [13, 14] . Thus, ESR signaling is critical for male reproductive function and fertility [15, 16] . SCs are the major source of estrogens in immature animals [17] , and in turn, estrogen-induced ESR signaling is important for the maintenance of SC function and number.
Components of dietary agents and natural products can be used for treating various diseases, and in recent years, researchers have paid great attention to steroid-like compounds in numerous dietary agents. Diosgenin, an important natural source of steroidal hormones in the pharmaceutical industry, has gained attention recently. As an aglycone of the steroidal saponin, diosgenin can be found in several plants, including Solanum and Dioscorea species, and is a principal raw material for the industrial production of steroid drugs. Diosgenin has various favorable effects, including regulation of lipid metabolism [18, 19] and antitumor effects [20, 21] . However, the effect of diosgenin on the proliferation of SCs is unknown.
The present study was designed to investigate the effect of diosgenin on SC proliferation and to elucidate the possible molecular mechanisms. The results showed that incubation in diosgenin (0.01-2.5 lM) significantly increased SC viability and proliferation. Diosgenin immediately stimulated SRCdependent plasma membrane translocation of ESR and subsequent phosphorylation of extracellular regulated protein kinase (ERK) and protein kinase B (Akt), then enhanced transcriptional activity of ESR in the nucleus, leading to promotion of cell-cycle progression and inhibition of apoptosis.
MATERIALS AND METHODS

Materials
b-Actin, Lamin B, cyclin-dependent kinase (CDK) 2, CDK4, CDK6, cyclin D1, cyclin B, cyclin E, cell division cycle 2 (cdc2), Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), and apoptosis-inducing factor (AIF) antibodies were purchased from Santa Cruz Biotechnology. a-Tubulin antibody was purchased from Bioworld Technology. Akt, P-Akt, ERK, P-ERK, P27, caspase 3, and caspase 9 antibodies were purchased from Cell Signaling Technology. Diosgenin, 17b-estradiol (E2), inhibitors, and the chemicals and reagents used in the present study were procured from Sigma unless otherwise indicated.
Primary SC Isolation and Cultures
Primary culture of rat SCs was prepared as previously described [22] . The rat SCs were purchased from American Type Culture Collection (ATCC). Animals were purchased from Animal Centre of Fourth Military Medical University. All animal experiments were approved by the Institutional Animal Care and Research Advisory Committee of the Fourth Military Medical University. Briefly, testes were removed, decapsulated, and dispersed into small pieces in PBS. The dispersed seminiferous tubules were then digested with 0.25% trypsin and 0.006% soybean trypsin inhibitor in Hanks Balanced Salt Solution for 5 min at room temperature and then centrifuged at 800 3 g for 5 min. Next, seminiferous tubules were saved, cut, and submitted to 0.1% collagenase IV for 30 min at 348C. Digested cell suspension was filtered through a 200-mesh filter and washed three times in culture medium consisting of a 1:1 mixture of Dulbecco modified Eagle medium and Ham F-12 (DMEM/ F-12; Gibco) supplemented with 5% fetal bovine serum (FBS).
The SCs were seeded in DMEM/F-12 medium with 5% FBS and cultured at 378C in a humidified 5% CO 2 -enriched atmosphere. At 48 h, cells were hypotonically treated with 20 mM Tris-HCl (pH 7.4) for 2 min, followed by two washes with PBS. The SC purity was more than 95%. The viability of purified SCs was more than 90% as judged by trypan blue staining. To evaluate the effects of diosgenin on cell proliferation, primary SCs were incubated with E2 (25-100 nM) or diosgenin (0.01-5 lM) for 0-48 h.
TM4 Cell Culture and Treatment
The TM4 mouse SCs were purchased from the ATCC. TM4 cells were grown in medium containing of DMEM/F-12 with 1.2 g/L of sodium bicarbonate and 15 mM Hepes (92.5%) plus 5% horse serum and 5% FBS supplemented with 100 U/ml of penicillin and 100 U/ml of streptomycin. Cells were incubated at 378C in a humidified 5% CO 2 -enriched atmosphere. SCs were allowed to grow until reaching 70%-80% confluence and then washed thoroughly, and the medium was replaced by serum-free medium (DMEM:F-12, pH 7.4). To evaluate the effects of diosgenin on cell proliferation, TM4 SCs were incubated with E2 (25-100 nM) or diosgenin (0.01-5 lM) for 0-48 h. In some experiments, TM4 SCs were treated with diosgenin (2.5 lM) in the presence or absence of the antiestrogen ICI 182 780 (1 nM), PP2 (5 nM; an inhibitor of SRC, U0126 (10 lM; an inhibitor of mitogen-activated protein kinase kinase/ERK), or LY294002 (10 lM; an inhibitor of phosphatidylinositol 3 0 -kinase/Akt) for the indicated experimental periods.
Cell Viability and Proliferation
Cell viability was determined using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dimethyl tetrazolium bromide assay; Sigma) at a final concentration of 0.5 mg/ ml. In brief, after treatments, 120 ll of culture medium containing MTT were added in each well, and the plate was incubated for 4 h at 378C. After that, the medium was removed, and the reaction product was solubilized in 150 ll of dimethyl sulfoxide. Absorbance was measured at 570 nm using a Tecan microplate reader. Cell proliferation was performed using a CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Kit (Promega) according to the manufacturer's instructions.
Cell-Cycle Analysis
Cell-cycle analysis was conducted as previously reported [23] . In brief, at the end of the treatment, SCs were fixed in 75% ethanol and filtered by 500-mesh to get the single-cell suspension. Then, cells were harvested and resuspended in a hypotonic fluorescent solution (50 mg/ml of propidium iodide and 0.1% Triton X-100 in 0.1% sodium citrate buffer) for 1 h at 48C in the dark. Cell-cycle distribution was analyzed by flow cytometry (BD Biosciences 2000). BD CellQuest Pro Analysis Tutorial software was used to conduct data acquisition and analysis. The results were expressed as percentage of the DNA, distributed in different stages.
TUNEL Assay
Apoptosis was determined by TUNEL staining. The TdT-FragEL DNA Fragmentation Detection Kit (Calbiochem) was used according to the manufacturer's instructions. The total number of cells and the number of TUNEL-positive SCs were counted in five random fields in a ''blinded'' manner. DNase was added into the sample before the TUNEL assay to establish positive controls. Replacement of the TdT enzyme by dH 2 O was conducted to create negative controls.
Protein Extraction
Nuclear protein was extracted by a NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce). Plasma protein was extracted by a Plasma Membrane Protein Extraction Kit (Abcam). Proteins were extracted according to the manufacturer's instructions.
Western Blot Analysis
After the treatment, proteins were extracted and separated by 10% SDS-PAGE and electrotransferred onto an NC membrane (Millipore). The membranes were blocked with 8% (w/v) skimmed milk in TBS (20 mM Tris-HCl [pH 7.5] and 150 mM NaCl). The membranes were incubated with primary antibodies overnight at 48C, then treated with horseradish peroxidaselabeled secondary antibody (Pierce) for 30 min at 378C. Bands were detected using the Pierce ECL Western Blotting Substrate kit (Thermo Scientific).
Transfections and Reporter Assays
The ERE Luciferase Reporter Assay Kit (Qiagen) was used according to the manufacturer's instruction, and plasmids were transfected into TM4 cells using a TurboFect Transfection Reagent (Thermo Scientific). Cells were harvested in 200 ll of Passive Lysis Buffer (Promega) and stored at À708C. Reporter assays were performed using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to that of Renilla luciferase and expressed as a ratio of relative light units.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (CHIP) was conducted using a Thermo Scientific Pierce Agarose ChIP Kit according to the manufacturer's instruction. After the treatment, cells were cross-linked using 1% formaldehyde. Then, cells were harvested, and cross-linked chromatin was sheared by sonication. Sonicated cell lysate was immunoprecipitated using ESR1 or ESR2 antibodies. DNA present in the immunoprecipitated chromatin was isolated after reversed cross-link, and PCR was performed to examine the presence of cyclin D1 and Bcl-2 gene promoters.
Statistical Analysis
All experiments were performed at least three times, and results are expressed as the mean 6 SEM. The results were analyzed by one-way analysis of variance followed by a SNK-q test for multiple comparisons. All analyses were performed using the Statistical Package for the Social Sciences software (version 13.0; SPSS). Data were considered to be statistically significant at P , 0.05. More specific indices of statistical significance are indicated in the individual figure legends.
RESULTS
Diosgenin Increases SC Viability and Proliferation
TM4 cells and primary SCs were incubated with diosgenin (0.01-5 lM) for 24 h, and then cell viability and proliferation were determined by MTT assay and a Proliferation Assay Kit, respectively. Diosgenin notably increased cell viability (maximum, 1.8-fold) and proliferation (maximum, 1.5-fold) of TM4 cells (Fig. 1, A and B) and primary SCs (Fig. 2, A and B), with the maximum increase at 2.5 lM. The diosgenin concentration of 2.5 lM was then selected for the rest of the study. Both in TM4 cells (Fig. 1 , C and D) and in primary SCs (Fig. 2 , C and D), administration of diosgenin (2.5 lM) for 6-48 h significantly increased cell viability and proliferation, with the maximum increase at 24 h.
In addition, we examined the effect of E2 on SC proliferation. As shown in Supplemental Figures S1 and S2 (available online at www.biolreprod.org), E2 (25-100 nM) significantly increased cell viability and proliferation of both TM4 cells and primary SCs in a concentration-and time-WU ET AL. dependent manner. These results demonstrated that although less efficient, diosgenin exhibited effects on SC proliferation similar to those of E2.
Diosgenin Promotes G 1 /S Cell-Cycle Transition and Inhibits Apoptosis in TM4 Cells
To study the mechanism of diosgenin-induced increase of cell viability and proliferation in SCs, cell-cycle distribution and apoptosis were detected. TM4 cells were treated with diosgenin (2.5 lM) for 16 h, and then cell cycle was analyzed by flow cytometry. As shown in Figure 3A , the cell population at the G 0 /G 1 phase was significantly decreased, whereas the cell population at the S phase was significantly increased. The results revealed no significant alterations of the cell population at the G 2 /M phase (Fig. 3A) . In addition, after a 16-h incubation of TM4 cells with diosgenin, key regulators of the cell cycle were evaluated by Western blot analysis. As shown in Figure 3 , B and C, shows that the protein expression of CDK4/6, cyclin D1, CDK2, and cyclin E was notably increased by diosgenin treatment. P27, a negative regulator of cell cycle, was evidently inhibited by diosgenin (Fig. 3, B and C). However, diosgenin exerted no significant effect on cdc2 and cyclin B expression (Fig. 3, B and C) .
In the next step, TM4 cells were incubated with diosgenin (2.5 lM) for 24 h, and then a TUNEL assay was conducted to evaluate the effect of diosgenin on apoptosis. As shown in Figure 3D , diosgenin remarkably inhibited apoptosis, as reflected by the decrease in TUNEL-positive cells. Furthermore, expression of apoptosis-related factors was detected by Western blot analysis. As shown in Figure 3 , E and F, that diosgenin notably inhibited the protein expression of Bax, AIF, cleaved caspase 3, and cleaved caspase 9 but increased Bcl-2 protein expression. These results indicated that diosgenininduced TM4 cell proliferation could be attributed to enhancement of cell-cycle transition and inhibition of apoptosis.
Diosgenin Promotes SRC-Dependent Plasma Membrane Translocation of ESR
To further determine the molecular mechanism of diosgenin-induced regulation on cell cycle and apoptosis, the expression and location of ESRs was examined. TM4 cells were incubated with diosgenin (2.5 lM) for 30 min, and then nuclear and plasma membrane proteins were extracted. As shown in Figure 4 , A and B, plasma membrane expression of ESR1 and ESR2 was immediately increased after treatment with diosgenin, with the maximum increase at 15 min. In FIG. 1 . Effect of diosgenin on the proliferation of TM4 cells. A) TM4 cells were incubated with diosgenin (0.01-5 lM) for 24 h, and then cell viability was determined by MTT assay. B) TM4 cells were incubated with diosgenin (0.01-5 lM) for 24 h, and then cell proliferation was determined by a commercial cell proliferation assay kit. C) TM4 cells were incubated with diosgenin (2.5 lM) for 6-48 h, and then cell viability was determined by MTT assay. D) TM4 cells were incubated with diosgenin (2.5 lM) for 6-48 h, and then cell proliferation was determined by a commercial cell proliferation assay kit. *P , 0.05, compared with control.
DIOSGENIN STIMULATES TM4 CELL PROLIFERATION contrast, nuclear expression of ESR1 and ESR2 was immediately decreased, with the maximum decrease at 15 min (Fig. 4,  C and D) . The results indicated that diosgenin induced an immediate translocation of ESR1 and ESR2 from the nucleus to the plasma membrane.
In addition, the antiestrogen ICI 182 780(1 nM) and the selective inhibitor of the SRC family of protein tyrosine kinases, PP2 (5 nM), were introduced to evaluate the effect of diosgenin on ESR translocation. As shown in Fig. 4 , E and F, diosgenin-induced plasma membrane translocation of ESR1 and ESR2 was significantly inhibited in the presence of ICI 182 780 and PP2. Consistently, diosgenin-induced decrease of nuclear ESR1 and ESR2 was blocked by PP2 (Fig. 4, G and  H) . These results demonstrated that diosgenin-induced translocation of ESR1 and ESR2 from the nucleus to the plasma membrane was dependent on protein tyrosine kinase SRC.
Furthermore, we determined the effect of ICI 182,780 (1 nM) and PP2 (5 nM) on diosgenin-induced SCs proliferation. As shown in Figure 4 , I and J, diosgenin-induced increase of cell viability and proliferation was notably inhibited by ICI 182 780 and PP2. Decrease of the G 0 /G 1 -phase cell population and increase of the S-phase cell population induced by diosgenin administration was inhibited in the presence of ICI 182 780 and PP2 (Fig. 4K) . Moreover, diosgenin-inhibited apoptosis was blocked by ICI 182 780 and PP2, as evidenced by the increase in TUNEL-positive cells (Fig. 4L) . These results indicated that SRC-dependent plasma membrane translocation of ESR1 and ESR2 was, at least in part, responsible for diosgenin-induced cell-cycle transition, inhibition of apoptosis, and thus SC proliferation.
Diosgenin Stimulates SRC-Dependent Activation of ERK and Akt Signaling
To detect the links between ESR translocation and cell proliferation induced by diosgenin, we evaluated ERK and Akt signaling after diosgenin treatment. As shown in Figure 5 , A and B, diosgenin (2.5 lM) immediately induced an increase of ERK phosphorylation, with the maximum increase at 15 min. In the presence of ICI 182 780 (1 nM) and PP2 (5 nM), diosgenin-induced phosphorylation of ERK was significantly suppressed (Fig. 5, C and D) . Similarly, after the treatment with diosgenin, phosphorylation of Akt was immediately stimulated, with the maximum increase at 15 min (Fig. 5, E and F) ,
FIG. 2. Effect of diosgenin on the proliferation of SCs.
A) Primary SCs were incubated with diosgenin (0.01-5 lM) for 24 h, and then cell viability was determined by MTT assay. B) Primary SCs were incubated with diosgenin (0.01-5 lM) for 24 h, and then cell proliferation was determined by a commercial cell proliferation assay kit. C) Primary SCs were incubated with diosgenin (2.5 lM) for 6-48 h, and then cell viability was determined by MTT assay. D) Primary SCs were incubated with diosgenin (2.5 lM) for 6-48 h, and then cell proliferation was determined by a commercial cell proliferation assay kit. *P , 0.05, compared with control.
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whereas ICI 182 780 and PP2 notably suppressed the increase of Akt phosphorylation induced by diosgenin (Fig. 5, G and  H) .
Next, we evaluated the role of ERK and Akt signaling in diosgenin-induced TM4 cell proliferation. As shown in Figure  5 , I and J, a specific inhibitor of mitogen-activated protein kinase kinase/ERK, U0126 (10 lM), remarkably blocked diosgenin-induced increase of cell viability and proliferation in TM4 cells. Consistently, diosgenin-induced increase of TM4 cell viability and proliferation was also suppressed by a specific inhibitor of phosphatidylinositol 3 0 -kinase/Akt, LY294002 (10 lM). These results implicated that stimulation of ERK and Akt signaling was involved in diosgenin-induced TM4 cell proliferation.
Diosgenin Increases SRC and ERK/Akt-Dependent ESR Transcriptional Activity
In the next step, we evaluated the effect of diosgenin on transcriptional activity of ESR in TM4 cells. TM4 cells were incubated with diosgenin (2.5 lM) for 12-48 h, and then nuclear expression of ESR1 and ESR2 was detected by Western blot analysis. As shown in Figure 6A , nuclear expression of ESR1 and ESR2 was significantly increased 12-48 h after the treatment with diosgenin, with the maximum increase at 24 h, which was opposite to the immediate effect of diosgenin on nuclear ESR1 and ESR2 expression (Fig. 4, C  and D) . Moreover, an ERE-luciferase reporter was used to evaluate ESR activity. As shown in Figure 6B shows, reporter activity was markedly increased 12-48 h after the treatment with diosgenin, with the maximum increase at 24 h. Furthermore, diosgenin-increased reporter activity was significantly suppressed by ICI 182 780 (1 nM), PP2 (5 nM), U0126 (10 lM) and LY294002 (10 lM), indicating that diosgenininduced early activation of SRC and ERK/Akt signaling was responsible for late up-regulation of ESR transcriptional activity.
To further explore the role of late activation of ESR in diosgenin-induced TM4 cell proliferation, we used the CHIP assay. As shown in Figure 6 , C and D, ESR1 and ESR2 was observed to bind with cyclin D1 promoter after the treatment with diosgenin. In addition, binding of Bcl-2 promoter by 
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ESR1 and ESR2 was also induced by diosgenin. These data demonstrated that diosgenin-induced late activation of ESR transcriptional activity was responsible for progression of the cell cycle and inhibition of apoptosis, leading to SC proliferation.
DISCUSSION
The adult SC population is established early in postnatal development [10, 11] . In rodents, SCs stop proliferating by Day 16 after birth [10, 11] , determining subsequent sperm production and overall testis size. In the present study, using the TM4 cell line, we investigated the effect of diosgenin on SC proliferation and explored the possible molecular mechanisms.
We found that diosgenin (0.01-2.5 lM) increased cell viability and proliferation both in TM4 cells and primary SCs in a concentration-and dose-dependent manner. Cell viability and proliferation is determined by the complex interaction of various processes, such as cell-cycle progress and apoptosis. The cell cycle is divided into mainly four phases, including the G 0 /G 1 , S, G 2 , and M (mitosis) phases. In response to growth or stress stimuli, cells exit from the quiescent G 0 phase and enter the active G 1 phase, then progress into the S phase, in which DNA is synthesized. The G 1 /S transition is followed by the G 2 / M transition, in which mitotic events occur. Under physiological conditions, cell-cycle progression is governed by a series of key regulators, including positive regulators (cyclins and CDKs) and negative regulators (CDK inhibitors). Cyclins D and E, interacting with their respective kinase partners, CDK4/ 6 and CDK2, regulate the G 1 /S transition. P27 is a CDK inhibitor, preventing the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and acts as a primary regulator of SC proliferation [24] . Cyclin B and cdc2 are responsible for regulating the G 2 /M cell-cycle transition. In the present study, we showed that diosgenin increased cyclins D1 and E as well as CDK4/6 and CDK2 expression but inhibited P27 expression, resulting in promotion of the G 1 /S transition.
Apoptosis is a fundamental programmed cell death pathway [25] . The members of the Bcl-2 family, consisting of anti-and proapoptotic members, such as Bcl-2 and Bax, are important mediators of apoptosis [26, 27] . In response to apoptotic signals, Bax translocates to the outer membrane of mitochondria, resulting in permeabilization of the outer mitochondrial membrane and release of many apoptosis-promoting proteins from the mitochondrial intermembrane space, including cytochrome c, AIF, and some procaspases [26] . This event is followed by sequential activation of effector caspases (e.g., caspase 3), leading to final cell death, which cannot be reversed [28] . In SCs of infertile men, apoptotic levels are significantly increased [29] . In the present study, we found that diosgenin could inhibit apoptosis of TM4 cells, as reflected in decreased TUNEL-positive cells; decreased expression of Bax, AIF, and cleaved caspases 3 and 9; and increased expression of Bcl-2. These data demonstrated that promotion of the G 1 /S cell-cycle transition and inhibition of apoptosis contributed to diosgenininduced SC proliferation.
Considering that diosgenin is a precursor for the synthesis of steroidal hormones, we further explored the probable role of estrogen/receptor signaling in diosgenin-induced regulation of SCs proliferation. We showed that E2 (25-50 nM) increased cell viability and proliferation in both TM4 cells and primary SCs in a dose-and time-dependent manner. The effect of E2 on SCs was similar to, and more efficient than, that of diosgenin, indicating that estrogen/receptor signaling may be involved in diosgenin-induced regulation of SCs proliferation. The biological effects of estrogen are mediated by the specific receptors ESR1 and ESR2 (also known as ERa and ERb, respectively), which are widely distributed in the male reproductive tract [30] [31] [32] . ESR1 is present in Sertoli, Leydig, and some peritubular myoid cells, and ESR2 is present in multiple cell types, including germ cells [33] [34] [35] [36] . Previous literature has reported that treatment of SCs with E2 induced a translocation of ESR1 and ESR2 to the plasma membrane [36] . Consistently, we found that diosgenin induced an immediate and transient plasma membrane translocation of ESR1 and ESR2 from the nucleus, which was dependent on activation of SRC, as evidenced by PP2-induced inhibition of ESR1 and ESR2 translocation in the presence of diosgenin. Moreover, antiestrogen ICI 182 780 and PP2 significantly blocked diosgenininduced G 1 /S cell-cycle transition and inhibition of apoptosis and thus TM4 cell proliferation. The data demonstrated that SRC-dependent activation of plasma membrane translocation of ESR1 and ESR2 was responsible diosgenin-induced TM4 cell proliferation.
Previous studies have shown that E2-induced plasma membrane translocation of ESR was followed by the activation of ERK signaling [36] . ERK is an important member of MAPK family of serine/threonine kinases that regulate proliferation, differentiation, migration, and apoptosis and that participate in a number of diseases through modulating transcription of genes in the nucleus. In the present study, we discovered that diosgenin induced an instant and transient activation of ERK signaling, which was inhibited by ICI 182 780, PP2, and U0126. Moreover, U0126 significantly suppressed diosgeninexhibited increase of TM4 cell viability and proliferation. The serine/threonine kinase signaling cascade phosphatidylinositol 3-kinase/Akt is critical for cell survival and proliferation under normal and pathological conditions. In the present study, we also assessed the effect of diosgenin on Akt signaling. The results showed that diosgenin induced an instant and transient activation of Akt signaling, which was inhibited by ICI 182 780, PP2, and LY294002. Moreover, LY294002 significantly blocked diosgenin-exhibited increase of TM4 cell viability and proliferation. These results demonstrated that SRC-and ESR-dependent activation of ERK/Akt signaling was responsible for diosgenin-induced TM4 cell proliferation. Under basal conditions, ESR1 and ESR2, as nuclear receptors, locate in the nuclei of SCs. In addition to instant activation of plasma membrane translocation, we evaluated the long-term effect of diosgenin on ESR1 and ESR2. We found that 12-24 h after the treatment, diosgenin significantly increased the transcriptional activity of ESR, as evidenced by increased nuclear expression and reporter activity of ESR. This increase of ESR transcriptional activity induced by diosgenin was blocked by ICI 182 780, PP2, U0126, and LY294002, indicating that SRC-ESR translocation and ERK/Akt signaling was responsible for diosgenin-induced activation of ESR transcriptional activity. Moreover, we found that ESR could bind with the promoters of cyclin D1 and Bcl-2, as reflected by the CHIP results, indicating that increase of ESR transcriptional activity could directly regulate cell-cycle progress [37] and apoptosis, leading to diosgenin-induced TM4 cell proliferation.
In conclusion, we found that diosgenin increased SC proliferation in a time-and concentration-dependent manner. Diosgenin induced instant and transient SRC-dependent plasma membrane translocation of ESR and subsequent activation of ERK/Akt signaling, followed by late activation of nuclear ESR transcriptional activity and direct transcriptional regulation of cell cycle and apoptosis regulators, such as cyclin D and Bcl-2, resulting in promotion of the G 1 /S transition and inhibition of apoptosis, finally leading to SC proliferation (Fig. 7) . These findings may better our understanding of the pharmacological actions of diosgenin and advance therapeutic approaches to male infertility. inhibitors (D) on estrogen receptor transcriptional activity. TM4 cells were cotransfected with ERE-luciferase and Renilla plasmids, and then cells were treated with diosgenin. Luciferase activity was determined with Stop & Glo (Promega), and firefly luciferase activity was normalized to that of Renilla luciferase. E-G) TM4 cells were treated with diosgenin (2.5 lM) for 24 h. The effect of diosgenin on the binding of ESR1 (E and G) and ESR2 (F and H) to the cyclin D1 (D and E) and Bcl-2 (F and G) promoter was assessed by CHIP assay. *P , 0.05 compared with control, #P , 0.05 compared with diosgenin treatment.
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